Blueprint Medicines Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Blueprint Medicines (BPMC) Tops Q2 EPS by 3c
August 9, 2016 7:48 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.70), $0.03 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $7.07 million versus the consensus estimate of $4.41 million.
Financial Guidance:
Blueprint Medicines expects that its cash, cash equivalents and investments balance... More
